Abstract
ObjectivesThere is limited qualitative research on patients’ experiences with long COVID-19, and how specific symptoms impact their daily lives. The study aimed to understand patients’ lived experiences of long COVID-19 and to develop a conceptual model representing the symptoms and their impact on overall quality of life.SettingQualitative study consisting of a comprehensive literature review, and in-depth clinician and patient semistructured interviews.ParticipantsForty-one adult patients with long COVID-19, of whom 18 (44%) were recruited through Regeneron Pharmaceuticals’s clinical trials and 23 (56%) through recruitment agencies; 85.4% were female and 73.2% were White. Five independent clinicians treating patients with long COVID-19 were interviewed. Concept saturation was also assessed.Primary and secondary outcomesInterview transcripts were analysed thematically to identify concepts of interest spontaneously mentioned by patients, including symptoms and their impacts on daily life, to guide the development of the conceptual model.ResultsFindings from the literature review and clinician and patient interviews resulted in the development of a conceptual model comprising two overarching domains: symptoms (upper respiratory tract, lower respiratory tract, smell and taste, systemic, gastrointestinal, neurocognitive and other) and impacts (activities of daily living, instrumental activities of daily living, physical impacts, emotional, social/leisure activities and professional impacts). Saturation was achieved for the reported impacts. The symptoms reported were heterogenic; neurocognitive symptoms, such as numbness, ringing in ears, haziness, confusion, forgetfulness/memory problems, brain fog, concentration, difficulties finding the right word and challenges with fine motor skills, were particularly pertinent for several months.ConclusionThe conceptual model, developed based on patient experience data of long COVID-19, highlighted numerous symptoms that impact patients’ physical and mental well-being, and suggests humanistic unmet needs. Prospective real-world studies are warranted to understand the pattern of long COVID-19 experienced in larger samples over longer periods of time.
Funder
Biomedical Advanced Research and Development Authority
Regeneron Pharmaceuticals
Office of the Administration for Strategic Preparedness and Response
Department of Health and Human Services
Reference47 articles.
1. Centers for Disease Control and Prevention . Long COVID or post-COVID conditions. Available: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html [Accessed 24 Sep 2022].
2. Post-acute COVID syndrome (long COVID): what should radiographers know and the potential impact for imaging services;Alghamdi;Radiography (Lond),2022
3. Central sensitization phenotypes in post acute sequelae of SARS-Cov-2 infection (PASC): defining the post COVID syndrome;Bierle;J Prim Care Community Health,2021
4. Long COVID: an overview;Raveendran;Diabetes Metab Syndr,2021
5. National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020. Available: https://www.nice.org.uk/guidance/ng188 [Accessed 24 Sep 2022].